Strong executive thought leadership can be a highly effective way for MedTech companies to engage and influence key stakeholders in 2026.
But most attempts are invisible to the people who matter.
In this article, we'll explore the reasons why MedTech executives are struggling to secure sales, what clinical buyers and procurement teams actually want to hear, and how to start building a communications strategy that works in 2026.
Why MedTech executives are failing to land with the people who actually buy
You've spent years developing a quality product and have recently placed it on the UK market. It's picked up attention in the trade press, and you've received a positive response on digital platforms, but your efforts aren't producing tangible sales.
The good news: for most MedTech companies, this isn't a sign that your product is unmarketable.
The root cause of poor sales is usually structural; your executive communications strategy is built for the wrong audience.
So, where do most MedTech companies go wrong?
The typical MedTech executive profile is tailored to investor relations and trade shows, including Medica, DMEA, and Arab Health. This is fine (and even recommended) in the early stages of development and marketing, but quickly becomes unproductive when a product reaches the market.
Reaching the teams that actually make procurement decisions requires a different strategy.
The NHS procurement process increasingly involves clinical leads, integrated care board commissioners, and health economists alongside traditional procurement teams. These audiences respond to corporate communications and B2B thought leadership backed by clinical evidence and delivered by credible, expert voices.
MedTech Executives who fail to speak the language of procurement teams lose credibility early and may be filtered out before a formal evaluation process has even begun. Successful thought leadership builds trust in a named individual over time, cementing them as a reference point for time-crunched decision-makers.
So, the problem isn't a lack of brand awareness in general, but a lack of executive visibility to the people who make procurement decisions. No amount of trade coverage alone will remedy this.
What NHS commissioners and clinical buyers actually need to hear
Clinical buyers have different priorities than investors. They respond to evidence of patient outcomes, real-world implementation data, and honest assessment of adoption challenges.
These priorities are largely shaped by operational context:
- Wider NHS financial constraints mean that procurement teams are deliberately seeking cost-effective products. A MedTech executive who can utilise QALY frameworks and comparative effectiveness to demonstrate improved patient outcomes at a relatively low cost will be better placed to win a contract than those who falter. An executive who cannot engage with the concepts fluently signals a company that will be difficult to work with through evaluation.
- Regulatory changes, including the recently implemented NHS Medical Technology Strategy, have placed a greater emphasis on interoperability. MedTech execs who can't provide evidence of system-fit will have little success marketing to NHS procurement teams.
- Clinical buyers have to make decisions under time pressure. They need credible evidence that's digestible, not the opaque marketing content many MedTech companies mistakenly lead with. A small change in framing can set you apart in a market of over 4000 competitors.
How should you prepare for a conversation with a procurement lead?
MedTech executives should familiarise themselves with the current policy and operational landscapes. If you understand the NHS' internal structure, the role of integrated care systems, and its overarching institutional priorities, you can successfully pitch your product through the language of procurement teams and lead with evidence that ticks boxes.
For example, an effective communications strategy in 2026 might lay out how a MedTech product aligns with NHS England's Delivery plan for reforming elective care.
Why MedTech communications default to the wrong channel and the wrong voice
MedTech executives typically default to the wrong channel and voice because they're following a strategy that centres investors and trade media, like Medtech Insight and Medtech Europe, rather than commissioners.
Although this approach generally works in early development, it struggles to achieve concrete sales when the product goes to market.
This is because peer- and investor-facing communications tend to default to product-first language instead of adopting the patient-first register that procurement teams expect to see. Feature-and-specification content, including press releases and funding announcements on digital platforms like LinkedIn, might appeal to investors, but generally misses the mark with clinical buyers.
MedTech executives need formal spokesperson training.
And this training must be tailored to a health policy or clinical audience. All too many MedTech companies mistakenly assume that one round of generic spokesperson training is enough to carry an executive through an entire product cycle, from development to sales.
But this raises the risk of miscommunication.
Under pressure, MedTech executives often revert to technical language, which reads as evasion or ignorance to a room of commissioners and clinicians.
As discussed in the previous section, procurement teams respond best to credible, transparent and evidence-backed communications from a named source. Executives can build voice-authority through engagement with clinical and trade publications, including the HSJ, BMJ and Integrated Care Journal. According to HSJ readership data, 18% of readers are commissioners, and an additional 27% are involved in commissioning.
The absence of a consistent, attributed executive voice in these channels is itself a signal. Silence in these outlets is not neutral; it's a positioning choice with direct consequences for sales. An executive that fails to engage with peer-reviewed commentary is near-invisible to the clinical audiences that matter.
What effective MedTech executive thought leadership actually looks like
We've explored the reasons why most MedTech executives struggle to build influence with clinical buyers, but what does effective thought leadership actually look like in 2026?
Executive thought leaders have the most success with procurement teams when they hone in on one or two wider system challenges and frame their MedTech product as the solution. You should ensure messaging is consistent; this encourages the target audience to associate a named executive with a problem the NHS has, rather than a product they sell.
Reaching the right audience requires the right communication channels.
Instead of trade shows and investor media, you should prioritise:
- Trade publications and peer-reviewed journals, including HSJ and the BMJ.
- Stakeholder engagement channels, e.g. NHS consultation responses and NICE stakeholder submissions. See the NHS' Stakeholder Engagement and Communications Plan for more information on the appropriate communication channels in 2026.
- Targeted engagement with integrated care system leads.
The format of executive communications also matters.
A single named opinion piece in HSJ is considered more credible, and carries more weight for a commissioning audience than 50 LinkedIn posts.
Traditional B2B corporate PR strategies utilise social media and can be useful for amplifying communications to a wider audience, but shouldn't replace engagement with high-authority channels. Peer-reviewed commentary, policy consultation responses, and clinical advisory board participation are more effective at reaching the people that matter.
Want more context on how the channel hierarchy functions in practice? Our dedicated insight breaks down the MedTech channels that build influence in 2026.
Delivery is key.
The most successful thought leaders in MedTech have been trained to speak in the register of clinical outcomes and system impact, not product features.
This is a skill that is built through deliberate preparation; it's rarely picked up by reading a briefing document before a meeting or by recycling generic PR training courses. MedTech executives should undergo structured media training tailored to clinical and policy audiences.
Where to start in 2026
Overhauling your MedTech communications strategy in 2026 can feel like a formidable task, and it's often unclear where you should start.
So, let's break it down.
Step one: audit the current executive footprint
- In which channels does the most senior voice in the business appear? If the answer doesn't contain any of the outlets or forums that matter to commissioning and clinical audiences, this is a good place to start.
Step two: identify one or two system challenges to target
- Make sure they're something the executive can credibly put forward a point of view on. Procurement teams want to hear a genuine position on a problem the NHS is trying to solve; product-adjacent messages disguised as policy commentary do not hit the mark.
Step three: build the channel plan around the commissioning audience
- You should update your communications strategy to reflect the priorities of clinical buyers, not investors. Target HSJ, BMJ, NHS Confederation platforms, and ICS engagement routes as the primary outlets, with trade and investor media as a secondary consideration.
Step four: invest in tailored media training for executive spokespeople
- Specifically, media training that's centred around clinical and policy audiences. Prepare spokespeople for real-life scenarios, including how to respond to the kinds of questions that a commissioner or health journalist will likely ask.
What next?
Following these steps will give you a solid foundation to build your wider communications strategy from. For further guidance, learn how Bridgehead works with healthcare and B2B organisations to help them reach the audience that matters.
